Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy

to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018 SOUTH SAN FRANCISCO, Calif., June 08, 2018 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in… Att fortsätt läsa